- $120.95m
- $107.23m
- $2.04m
U.S. STOCKS ON THE MOVE-Darden Restaurants, Mastercard, Accenture
U.S. STOCKS ON THE MOVE-Darden Restaurants, Mastercard, Accenture
U.S. STOCKS ON THE MOVE-Rivian, Biohaven, CervoMed
Humacyte falls after $20 million direct stock deal
Brief: Humacyte Submits Marketing Authorization Application For Symvess® In Israel For Vascular Trauma Repair
Humacyte rises on Department of Defense funding for lab-made blood vessels
Brief: Humacyte Announces New U.S. Department Of Defense Funding For Procurement Of Bioengineered Blood Vessels
Brief: Humacyte Inc Announces Planned Marketing Authorization Application For Symvess In Israel
Brief: Humacyte May Offer And Sell Shares Of Common Stock Of Up To $60 Million From Time To Time Through Td Cowen, Acting As Agent
Brief: Humacyte Announces Credit Facility Of Up To $77.5 Million With Avenue Capital
Brief: Humacyte Terminates Revenue Interest Purchase Agreement
Brief: Humacyte - On Nov 21, Co Delivered Notice To Jefferies Terminating Open Market Sale Agreement Entered On Sept 1, 2022
Biotech Humacyte's Q3 net income beats expectations as Symvess sales rise
Brief: Humacyte Q3 Operating Expenses USD 25.143 Million
Brief: Humacyte To Present Third Quarter Financial Results And Provide Business Update On November 12, 2025
Brief: Humacyte Announces Pricing Of $60.0 Million Oversubscribed Registered Direct Offering
Brief: Humacyte Inc Files For Mixed Shelf Of Up To $350 Million - SEC Filing
Humacyte Inc reports results for the quarter ended June 30 - Earnings Summary
Humacyte Inc expected to post a loss of 16 cents a share - Earnings Preview